Results 51 to 60 of about 784,391 (328)

Comparing self‐reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models

Molecular Oncology, EarlyView.
Integrating ancestry, differential methylation analysis, and machine learning, we identified robust epigenetic signature genes (ESGs) and Core‐ESGs in Black and White women with endometrial cancer. Core‐ESGs (namely APOBEC1 and PLEKHG5) methylation levels were significantly associated with survival, with tumors from high African ancestry (THA) showing ...
Huma Asif, J. Julie Kim
wiley   +1 more source

ANALYSIS MULTILEVEL SURVIVAL DATA USING COVARIATE-ADJUSTED FRAILTY PROPORTIONAL HAZARDS MODEL

Media Statistika
Multilevel survival data is time-to-event data with a hierarchical or nested structure. This study aims to model the data using the Covariate-Adjusted Frailty Proportional Hazards method, which is an extension of the Cox proportional hazards model with ...
Krismona Sandelvia, Adhitya Ronnie Effendie   +1 more
doaj   +1 more source

PENERAPAN REGRESI COX PROPORTIONAL HAZARD UNTUK MENDUGA FAKTOR-FAKTOR YANG MEMENGARUHI LAMA MENCARI KERJA

E-Jurnal Matematika, 2013
Survival analysis is a statistical method that accommodates the collection of censored data. One of popular method in survival analysis is the Cox Proportional Hazard Regression.
I GEDE ARI SUDANA, NI LUH PUTU SUCIPTAWATI, LUH PUTU IDA HARINI   +2 more
doaj   +1 more source

An exact corrected log-likelihood function for Cox's proportional hazards model under measurement error and some extensions [PDF]

, 2002
This paper studies Cox`s proportional hazards model under covariate measurement error. Nakamura`s (1990) methodology of corrected log-likelihood will be applied to the so called Breslow likelihood, which is, in the absence of measurement error ...
Augustin, Thomas
core   +1 more source

A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival

Molecular Oncology, EarlyView.
There is an unmet need in metastatic breast cancer patients to monitor therapy response in real time. In this study, we show how a noninvasive and affordable strategy based on sequencing of plasma samples with longitudinal tracking of tumour fraction paired with a statistical model provides valuable information on treatment response in advance of the ...
Emma J. Beddowes, Mario Ortega Duran, Solon Karapanagiotis, Alistair Martin, Meiling Gao, Riccardo Masina, Ramona Woitek, James Tanner, Fleur Tippin, Justine Kane, Jonathan Lay, Anja Brouwer, Stephen‐John Sammut, Suet‐Feung Chin, Davina Gale, Dana W. Y. Tsui, Sarah‐Jane Dawson, Nitzan Rosenfeld, Maurizio Callari, Oscar M. Rueda, Carlos Caldas   +20 more
wiley   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice

BMC Medical Research Methodology, 2019
Background Most clinical trials with time-to-event primary outcomes are designed assuming constant event rates and proportional hazards over time. Non-constant event rates and non-proportional hazards are seen increasingly frequently in trials.
Kim Jachno, Stephane Heritier, Rory Wolfe   +2 more
doaj   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Estimation in Cox proportional hazards model with heteroscedastic errors in covariates

Modern Stochastics: Theory and Applications
Consistent estimators of the baseline hazard rate and the regression parameter are constructed in the Cox proportional hazards model with heteroscedastic measurement errors, assuming that the baseline hazard function belongs to a certain class of ...
Oksana Chernova
doaj   +1 more source

An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect [PDF]

, 2014
Background: Most randomized controlled trials with a time-to-event outcome are designed and analysed under the proportional hazards assumption, with a target hazard ratio for the treatment effect in mind. However, the hazards may be non-proportional.
D Stark, DR Cox, FMS Barthel, FMS Barthel, KS Thomas, M Schemper, Mahesh KB Parmar, P Royston, P Royston, P Royston, Patrick Royston, PK Andersen, PM Grambsch, TS Mok, WP McGuire   +14 more
core   +2 more sources